QIAGEN N.V. (QGEN)
Pre-market:
| Previous close | 41.65 |
| Open | 41.88 |
| Bid | 42.30 x 800 |
| Ask | 42.28 x 800 |
| Day's range | 41.86 - 42.35 |
| 52-week range | 34.74 - 47.70 |
| Volume | |
| Avg. volume | 1,045,687 |
| Market cap | 9.363B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 27.65 |
| EPS (TTM) | 1.53 |
| Earnings date | 30 Apr 2024 |
| Forward dividend & yield | 1.28 (2.94%) |
| Ex-dividend date | 30 Jan 2024 |
| 1y target est | 50.98 |
ZacksHere's What Key Metrics Tell Us About Qiagen (QGEN) Q1 Earnings
While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ZacksQiagen (QGEN) Surpasses Q1 Earnings and Revenue Estimates
Qiagen (QGEN) delivered earnings and revenue surprises of 4.55% and 0.73%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- Globe Newswire
QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance
Q1 2024: Net sales of $459 million (-5% actual rates, -5% constant exchange rates, CER); diluted EPS of $0.36 and adjusted diluted EPS of $0.46 // Net sales at CER of $462 million ahead of outlook for at least $455 million CER and adj. diluted EPS of $0.47 CER ahead of $0.44 CER outlook // Excluding COVID-19 product groups, net sales decline 1% CER // Diagnostics sales +5% CER on double-digit CER growth in QuantiFERON and QIAstat‑Dx // 25.7% adjusted operating income margin on efficiency gains v
